ENDLOS-TURBO PUT - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 18:04:59 08/07/2024 BST | ||
| 18.26 EUR | -2.87% |
|
| Current month | -2.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 08/07/24 | 18.26 | -2.87% |
| 05/07/24 | 18.8 | -1.00% |
| 04/07/24 | 18.99 | -1.61% |
| 03/07/24 | 19.3 | +2.01% |
| 02/07/24 | 18.92 | -1.10% |
Real-time Boerse Frankfurt Warrants
Last update July 08, 2024 at 06:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DQ39DB |
| ISIN | DE000DQ39DB5 |
| Date issued | 07/06/2024 |
| Strike | 676.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 17.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.86 € |
|---|---|
| Lowest since issue | 17.41 € |
| Spread | 0.03 € |
| Spread % | 0.16% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Certificates
- Certificat
